Acurx Pharmaceuticals, Inc.
Filed Oct 20, 2025.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Oct 20, 2025
ACXP$1.06+12.1%Stored close · as of Nov 6, 2026
Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
| · | our ability to obtain and maintain regulatory approval of ibezapolstat and/or our other product candidates; |
| · | our ability to successfully commercialize and market ibezapolstat and/or our other product candidates, if approved; |
| · | our ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately; |
| · | the potential market size, opportunity and growth potential for ibezapolstat and/or our other product candidates, if approved; |
| · | our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize ibezapolstat and/or our other product candidates, if approved; |
| · | the timing of anticipated regulatory filings; |
| · | our ability to recruit and enroll suitable patients in our clinical trials and the timing of enrollment; |
| · | the timing or likelihood of the accomplishment of various scientific, clinical, regulatory and other product development objectives; |
| · | the development of major public health concerns, including the coronavirus outbreak or other pandemics arising globally, and the future impact of it and COVID-19 on our clinical trials, business operations and funding requirements; |
| · | the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the conflict between Russia and Ukraine as well as the conflict in the Middle East between Israel and Hamas; |
| · | our financial performance; |
| · | our ability to comply with the listing requirements of The Nasdaq Capital Market and maintain the listing of our common stock; and |
| · | other factors described from time to time in documents that we file with the SEC. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.